Figure 2From: Prospective double-blind randomized study on the efficacy and safety of an n-3 fatty acid enriched intravenous fat emulsion in postsurgical gastric and colorectal cancer patientsDistribution of mean (SD) during the study period. (a) IL-6, (b) CRP, (c) TNF-α, (d) PCT. *Follow up was defined as 30 days after last treatment.Back to article page